Get started
Author

Seiichi Imanishi

Observed names: S Imanishi, S. Imanishi
ORCID: 0000-0003-4335-4514
Observed ORCID: 0000-0003-4335-4514
OpenAlex ID: A5081656686
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
2016 · Katsuhiko Nakatsukasa, Hiroshi Koyama, et al. · Breast Cancer · 50
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer
2022 · Nabeel Kajihara, Takuto Kobayashi, et al. · Cancer Immunology Immunotherapy · 26
Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC
2019 · Seiichi Imanishi, Yasuto Naoi, et al. · Breast Cancer Research and Treatment · 25
Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
2016 · Katsuhiko Nakatsukasa, Hiroshi Koyama, et al. · Breast Cancer · 13
Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi‑institutional registry study
2023 · Yasuto Naoi, Ryo Tsunashima, et al. · Oncology Letters · 6
PDF
Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple-negative breast cancer
2022 · Seiichi Imanishi, Hirotaka Morishima, et al. · Japanese Journal of Clinical Oncology · 2
PDF
Age-dependent relative and absolute benefit of radiotherapy after breast-conserving surgery: a population-based analysis using SEER data
2026 · Seiichi Imanishi, Namiko Tanaka, et al. · Breast Cancer Research and Treatment · 1
Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies
2025 · Aya Imai, Ryo Tsunashima, et al. · Breast Cancer · 1
PDF
Possibility of Human Epidermal Growth Factor Receptor 2 Expression as a Treatment Selection Indicator in Early Triple-Negative Breast Cancer
2024 · Namiko Tanaka, Seiichi Imanishi, et al. · Cureus · 1
PDF
Significance of PDL1 positive in TNBC.
2020 · Seiichi Imanishi, Hirotaka Morishima, et al. · Journal of Clinical Oncology · 1
[Analysis of the Side Effects of Docetaxel with Cyclophosphamide (TC Therapy)].
2015 · Seiichi Imanishi, Hiroshi Koyama, et al. · PubMed · 1
Copy Number–Based Chromosomal Instability Ex-Score Predicts Breast Cancer Malignancy
2026 · Chise Matsui, Seiichi Imanishi, et al. · Research Square
PDF
Successful BRCA2 Mutation Detection via Tissue-Based Gene Panel Testing in Post-bone Marrow Transplant Breast Cancer: Implications for Precision Medicine
2025 · Chisato Takeuchi, Seiichi Imanishi, et al. · Cureus
PDF
206P Significance of the effects of chemotherapy on programmed death-ligand 1 expression in triple negative breast cancer
2020 · S. Imanishi, H. Morishima, et al. · Annals of Oncology
Abstract P3-11-06: HRD (homologous recombination deficiency) score and its clinicopathological features in neoadjuvant chemotherapy treated sporadic breast cancers
2019 · S Imanishi, Y Naoi, et al. · Cancer Research
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2- primary breast cancer.
2014 · Katsuhiko Nakatsukasa, Tetsuya Taguchi, et al. · Journal of Clinical Oncology
Works count: 16
Citation count: 127
H-index: 5
I10-index: 4
Year
Topic
Type